Objective: To determine whether extremely low birth weight infants who receive enteral sterile water have a reduction in treated patent ductus arteriosus or death by 28 days compared to infants with routine management.
Introduction
Fluid and electrolyte management during the first week of life in extremely low birth weight infants (ELBW, <1000 g) remains challenging. High fluid intake (traditionally given by the intravenous (i.v.) route) has been associated with the occurrence of a patent ductus arteriosus (PDA) in ELBW infants. [1] [2] [3] High fluid intake and PDA have been associated with the development of bronchopulmonary dysplasia (BPD). 4, 5 Other studies have not confirmed these findings. 6, 7 If higher fluid intake leads to a PDA, it is unknown whether fluid administered by the enteral route has the same effect as fluid given i.v.
Sterile water given by gastric drip (SWGD) has been used by some in ELBW infants in an effort to increase free water intake without increasing sodium or glucose intake. Gaylord 8 retrospectively evaluated the use of supplemental SWGD in premature infants (10 infants managed with SWGD and 20 controls). In this study, infants managed with SWGD showed improved electrolyte balance and decreased need for treatment of hyperkalemia. No complications from the use of SWGD were noted. Other studies have used water by gavage drip as part of an enteral feeding regimen and found no complications associated with SWGD. [9] [10] [11] Olney et al. 12 conducted the only published randomized trial of SWGD in 60 ELBW infants. In this trial, infants in the SWGD group could receive up to 30 ml kg À1 per day of SWGD. There were no differences in total fluid intake or in the incidence of hypernatremia, hyperkalemia, hyperglycemia or hyperbilirubinemia. Interestingly, there was an unanticipated significant reduction in treated PDA in the SWGD group (36 vs 69%, P ¼ 0.02, relative risk (RR) ¼ 0.52, 95% confidence interval (CI) 0.30 to 0.90), but not in the incidence of intracranial hemorrhage (ICH), necrotizing enterocolitis (NEC) or BPD.
This interesting finding led us to speculate that the route of fluid administration (i.v. vs enteral) may have different physiologic effects on the ELBW infant and, therefore, influence the likelihood of developing a PDA. Although this finding may not have strong physiologic foundations, our goal was to confirm or deny our previous unexpected but potentially important observation. Furthermore, we sought to conduct a larger trial that would allow us to address more rigorously the safety and tolerability of SWGD. The hypothesis of this larger randomized controlled trial was that sterile water provided by continuous orogastric gavage (up to 50 ml kg À1 per day) to ELBW premature infants would reduce the incidence of treated PDA and/or death by 28 days and would not increase the incidence of ICH, NEC or BPD.
Methods
This randomized trial was conducted in the neonatal intensive care units (NICU) of the Children's Memorial Hermann Hospital and Harris County Hospital District/ Lyndon Baines Johnson General Hospital. The Committee for the Protection of Human Subjects of the University of Texas Medical School at Houston and both hospitals approved the trial.
Eligibility criteria included infants who were <31 weeks gestation by Ballard examination 13 with birth weights X400 and p1000 g and who could be enrolled before 36 h of age. Exclusion criteria included severe asphyxia (defined as initial infant arterial blood (pH <7.1) and evidence of end-organ dysfunction), chromosomal abnormalities, major congenital anomalies, hypotension treated with dopamine or dobutamine >15 mg kg min À1 , or anticipated death (pH <6.80 or hypoxia with bradycardia for >2 h). After determining infant eligibility, written informed consent was obtained by study personnel. Infants were stratified by birth weight (400 to 750 g; 751 to 1000 g) and then randomized to the SWGD or control group using sequentially numbered, opaque, sealed envelopes.
Total fluid intake and type of i.v. fluid for the infants in the trial were determined by the attending physician. Fluid and sodium intake were adjusted to maintain the serum sodium level between sodium 135 and 145 mEq per 100 ml. The glucose infusion rate was adjusted to maintain the serum glucose between 40 and 180 mg per 100 ml.
In the intervention group, enteral SWGD was administered by oral gavage tube for a maximum of 7 days or until enteral feedings were initiated, whichever occurred earlier. At enrollment, planned fluid intake in excess of 80 ml kg À1 per day was administered by gavage in the SWGD group, to a maximum of 50 ml kg À1 per day (total fluid intake of 130 ml kg À1 per day). Any planned fluid intake in excess of 130 ml kg À1 per day was delivered by increasing the i.v fluid. During the 7-day intervention period, as the total fluid intake was modified, the SWGD was adjusted to provide the fluid intake between 80 and 130 ml kg À1 per day. In the control group, SWGD was not used at any point during the study; any need to increase the amount of total fluids was met by increasing the amount of i.v. fluid unless the attending physician decided to start enteral feedings. The intervention (SWGD) was not masked.
All infants enrolled in the study were placed under a radiant warmer and covered with clear plastic wrap for the 7-day study period. Humidified incubators were not used in the NICU during the study period. All stool specimens were tested for occult blood. Gastric residuals and abdominal girths were measured every 8 h in all infants. Early in the study, Aquaphor was used in all 400 to 750 g infants because of preliminary evidence suggesting reduced insensible fluid loss and a reduction in the risk of sepsis.
14,15 After 37 infants had been enrolled, additional evidence revealed that the risk of Candida sepsis might be greater with the use of Aquaphor and in January 2001, this practice was prohibited for study infants. 16 Outcome data were collected from admission to discharge or transfer. The diagnosis of PDA was based on the presence of a holosystolic murmur, hyperactive left ventricular impulse, increased pulse pressure, or tachycardia or tachypnea. PDAs were confirmed by echocardiogram before treatment. Treated PDA was defined as a PDA treated with either indomethacin, surgical closure or both. For consistency and to minimize bias, the daily study electrolyte values were obtained from the specimen collected closest to 0400 hours each day. Electrolyte abnormalities were diagnosed by the most extreme values obtained at any time during the 7-day study period. Definitions for electrolyte abnormalities were: hyponatremia, serum sodium <125 mEq l
À1
; hypernatremia, serum sodium >150 mEq l À1 ; hypoglycemia, serum glucose <40 mg per 100 ml; hyperglycemia, serum glucose >180 mg per 100 ml; hypokalemia, serum potassium <2.5 mEq l À1 and hyperkalemia, serum potassium >7.0 mEq l À1 . Hyperbilirubinemia was defined as a total serum bilirubin level of X8.0 mg per 100 ml. Acute renal failure was defined as oliguria (urine output <0.8 ml kg h À1 ) and creatinine >1.5 with no response to saline fluid boluses or i.v. diuretics. The definition of NEC was based on Bell's staging criteria. 17 ICH was graded according to Papile's criteria. 18 Cranial ultrasounds were routinely performed at 7 to 14 days of age and at 38 to 40 weeks postmenstrual age or discharge if this occurred sooner. BPD was defined as supplemental oxygen treatment beyond 28 days of age and abnormalities on a chest X-ray. Chronic lung disease (CLD) was defined as supplemental oxygen treatment at 36 weeks postmenstrual age.
Sample size was calculated using 'treated PDA' as the primary outcome. Review of the Children's Memorial Hermann Hospital database from May 1998 to June 1999 revealed an incidence of treated PDA in this patient population of 62%. Using a two-tailed a of 0.05 and a power of 0.80, to demonstrate a 30% relative reduction in treated PDA in the SWGD group, a total of 214 infants were needed. There were no interim analyses. The infants in the previous trial from our center were not included in this study. 12 All infants were analyzed in their assigned groups (intention-totreat). Data were analyzed using Number Cruncher Statistical Systems 2004, Kaysville, UT. RR ratios and the 95% CIs were calculated for the primary and secondary outcomes, as well as other categorical clinical outcomes. The Mann-Whitney U-test was used to compare continuous variable outcomes. For intentionto-treat analyses of duration of ventilation and duration of hospital stay, infants who died were assigned a 'worst outcome' (higher value than all surviving subjects) in a nonparametric analysis. Infants who were transferred to another hospital before discharge home were excluded from the duration of ventilation and duration of hospital stay analyses. Serial measurements of continuous outcomes were compared with repeated-measures analysis of variance (ANOVA) (Figure 1 ).
Results
From March 2000 to November 2003, 214 patients were enrolled. Of them, 105 were randomized to the control group and 109 to the SWGD group. There were 199 infants who were eligible but not enrolled due to the following reasons: parental refusal (46%), consent not requested (18%) and parents unavailable (11%). There were 50 infants who were eligible but were not approached for consent while the study was on administrative hold due to lack of funding from September 2001 to April 2002. Nine infants in the SWGD group and nine infants in the control group were transferred to another hospital before discharge home.
Baseline characteristics of the groups are displayed in Table 1 . There were no significant differences between the groups. Figure 2 shows the daily results by group for enteral and parenteral fluid intake. No differences were detected in total fluid intake, in daily weights (not shown) or urine output.
The proportion of infants with the primary outcome of treated PDA or death before 28 days of age was not significantly different between groups (SWGD 64% vs Control 63%, RR 0.99 (0.81, 1.22)). All but one of the infants with PDA had the diagnosis confirmed by echocardiography. There were no differences between groups for the proportion of infants with treated PDA among 28-day survivors, Tables 2 and  3 . There were no significant differences between the groups in any of these outcomes. Figure 3 shows the daily serum glucose and electrolyte concentrations. Daily mean serum glucose levels were significantly higher (P ¼ 0.04 by repeated-measures ANOVA, group effect) in the control infants. There were no significant differences in serum sodium and potassium levels between the groups.
Among those randomized to the SWGD group, the SWGD was not started in 1 infant and discontinued before the planned end of the intervention in 30 of 108 (28%) for the following reasons: discretion of attending physician in 11 (10%), intolerance (gastric residuals/emesis exceeding >3 Â the hourly rate) in 8 (7%), abdominal distention in 4 (4%), other reasons in 5 (5%) and surgery precluding enteral feedings in 2 (2%). Another 33 (30%) infants had the SWGD discontinued as planned when enteral feedings were started during the study. Of the 88 infants who completed the SWGD intervention (until 7 days or initiation of feedings), 70 had the SWGD transiently held for intolerance (increased gastric residual volume or increased abdominal girth) and then resumed without further problems. One infant in the control group was given a minimal amount of sterile water by gavage (9 ml kg À1 ) for part of 1 day.
Discussion
On the basis of the results of this study, we conclude that SWGD used up to a maximum of 50 ml kg À1 per day during the first week of life in ELBW infants does not reduce the incidence of treated PDA or death by 28 days. We had hypothesized that using SWGD may reduce the incidence of PDA based on findings from our previous randomized study. 12 The primary outcome for the current study, a treated PDA, occurred in about two-thirds of the infants in both groups. Although there could have been bias in the diagnosis of PDA as the attendings were not masked, the incidence of treated PDA in this study is comparable to that from the control group in our previous study 12 and also from our historical data. There are several potential explanations for the discordant findings from these studies, which were conducted at the same NICUs but used different maximum volumes of SWGD (30 vs 50 ml kg À1 per day). The most likely explanation for a statistically significant difference in a secondary outcome that is not confirmed in a larger randomized study of the same intervention is that the finding occurred by chance in the original study.
The proportion of infants with death or CLD at 36 weeks (70 to 77%) appears to be somewhat higher than other reports. Oh et al. 19 recently reported a 58% risk of death or BPD among infants 401 to 1000 g birth weight, although wide variation among centers has been reported in other studies. These authors reported an association between higher early fluid intake and the risk of BPD in ELBW infants. The fluid intakes in our study were comparable to those of the infants who died or developed BPD in the study by Oh et al. Whether there is a causal relationship between early fluid intake and BPD cannot be determined from these observational analyses but randomized trials have also reported a causal role of early fluid management in the development of BPD. 20 The diagnosis of hyperglycemia was less common in the intervention group (SWGD 43%; Control 53%; RR 0.81, 95% CI 0.61, 1.07), although this did not reach statistical significance. However, there were clinically meaningful differences in the median daily glucose level between the groups as demonstrated in Figure 3 . In the SWGD group these findings probably reflect the lower glucose intake due to the use of SWGD in place of a dextrosecontaining i.v. fluid. Hyperglycemia has been reported as a frequent problem in small premature infants. Dweck and Cassady 21 reported that 86% of infants with birth weight <1100 had hyperglycemia while receiving parenteral alimentation. Louik et al. 22 reported that the rate of hyperglycemia in infants who were receiving 10% dextrose infusions was 29% among those under 1000 g as compared to 1.6% in babies weighing more than 2 kg. Sterile water gavage drip in ELBW infants CD Stewart et al Abbreviations: DOL, day of life; NEC, necrotizing enterocolitis; PDA, patent ductus arteriosus; SWGD, Sterile water by gastric drip. This is thought to be due to relative insulin resistance in ELBW infants. 23 We have recently reported that persistent severe hyperglycemia (serum glucose>180 mg per 100 ml) in the first days after birth is associated with a higher risk of death and sepsis among ELBW infants. 24 Most of the infants completed the full 7-day study intervention and appeared to tolerate the SWGD reasonably well, although the intervention was transiently interrupted in about 80% of them. It is rather common among ELBW infants to have residuals or lack of tolerance when enteral feedings are begun. Our previous trial of SWGD and other studies of minimal enteral feedings have used lower volumes than we administered in this study. Even with the larger volume SWGD, there was no effect on the incidence of NEC, which occurred in a relatively small proportion of infants from both groups. A much larger study would be needed to demonstrate with more certainty that the incidence of NEC is not increased with SWGD. The incidences of other adverse outcomes were comparable to those reported in other large trials of ELBW infants. 25, 26 Our research group has now conducted the only two randomized trials of SWGD in which a total 274 infants have been enrolled and 139 infants received this intervention. No major adverse clinical outcomes related to the use of SWGD have been noted in these infants. The recent observations of poor outcomes associated with hyperglycemia in ELBW infants 22 and pediatric patients 27 and the improved outcomes reported with more aggressive treatment of hyperglycemia in critically ill adults 28, 29 suggest that a more aggressive approach for the prevention and treatment of hyperglycemia, which might include SWGD, warrants investigation in ELBW infants. Although our trial did not demonstrate the hypothesized benefit of SWGD, it represents a methodologically sound evaluation of the potential usefulness, or lack thereof, of a therapy that may be widespread in NICUs. Figure 3 Daily median serum glucose daily glucose levels (with 10th, 25th, 75th, 90th percentiles) (a), daily mean serum sodium (b) and daily mean serum potassium (c) levels by group.
